Thermo Fisher Scientific (NYSE:TMO) Shares Unloaded Rep. Kelly Morrison

Key Points

• Representative Kelly Morrison sold shares of Thermo Fisher Scientific valued between $1,001 and $15,000 on August 19th, 2025, as disclosed in a filing.
• Thermo Fisher Scientific's stock price recently dropped by 2.4%, trading at $479.48, while the company reported a $10.86 billion revenue for the last quarter, exceeding analyst estimates.
• The company announced a quarterly dividend of $0.43 per share, to be paid on October 15th, with a current dividend yield of 0.4%.

Representative Kelly Morrison (D-Minnesota) recently sold shares of Thermo Fisher Scientific Inc. NYSE: TMO. In a filing disclosed on September 11th, the Representative disclosed that they had sold between $1,001 and $15,000 in Thermo Fisher Scientific stock on August 19th. The trade occurred in the Representative's "TRUST 4" account.

Representative Kelly Morrison also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Verizon Communications NYSE: VZ on 8/19/2025.
• Sold $1,001 - $15,000 in shares of Johnson & Johnson NYSE: JNJ on 8/19/2025.
• Sold $15,001 - $50,000 in shares of Accenture NYSE: ACN on 8/19/2025.
• Sold $1,001 - $15,000 in shares of Accenture NYSE: ACN on 8/19/2025.
• Sold $15,001 - $50,000 in shares of Thermo Fisher Scientific NYSE: TMO on 8/19/2025.

Thermo Fisher Scientific Trading Down 2.4%

Shares of Thermo Fisher Scientific stock traded down $11.93 during trading on Friday, hitting $479.48. The stock had a trading volume of 1,543,232 shares, compared to its average volume of 1,555,589. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $623.77. The firm's fifty day simple moving average is $466.86 and its 200-day simple moving average is $451.08. The stock has a market cap of $181.06 billion, a PE ratio of 27.73, a PEG ratio of 2.62 and a beta of 0.75. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The company had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. During the same quarter last year, the business posted $5.37 EPS. The firm's revenue for the quarter was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 0.4%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio (DPR) is 9.95%.

Analyst Upgrades and Downgrades

TMO has been the subject of several recent research reports. Barclays upgraded shares of Thermo Fisher Scientific from an "equal weight" rating to an "overweight" rating and boosted their price objective for the stock from $490.00 to $550.00 in a research note on Thursday. Wells Fargo & Company reduced their price objective on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating for the company in a research note on Thursday, July 24th. Raymond James Financial reiterated an "outperform" rating and set a $535.00 price objective (up previously from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. HSBC reiterated a "hold" rating and set a $510.00 price objective on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Finally, William Blair began coverage on shares of Thermo Fisher Scientific in a research note on Monday, August 18th. They set an "outperform" rating for the company. Seventeen investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $592.24.

Insiders Place Their Bets

In other news, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the sale, the executive vice president directly owned 22,367 shares in the company, valued at $10,735,712.66. This represents a 1.76% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CAO Joseph R. Holmes sold 385 shares of the stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $492.63, for a total transaction of $189,662.55. Following the completion of the sale, the chief accounting officer owned 2,319 shares of the company's stock, valued at $1,142,408.97. This trade represents a 14.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 30,066 shares of company stock worth $14,182,963. Company insiders own 0.33% of the company's stock.

Institutional Trading of Thermo Fisher Scientific

A number of hedge funds have recently added to or reduced their stakes in TMO. Norges Bank purchased a new stake in Thermo Fisher Scientific during the second quarter worth $2,264,615,000. GAMMA Investing LLC boosted its holdings in Thermo Fisher Scientific by 60,610.9% during the first quarter. GAMMA Investing LLC now owns 2,419,331 shares of the medical research company's stock worth $1,203,859,000 after buying an additional 2,415,346 shares in the last quarter. Soundwatch Capital LLC acquired a new position in Thermo Fisher Scientific during the second quarter worth $807,713,000. Flossbach Von Storch SE raised its position in Thermo Fisher Scientific by 93.0% during the second quarter. Flossbach Von Storch SE now owns 2,727,021 shares of the medical research company's stock worth $1,105,698,000 after acquiring an additional 1,314,182 shares during the period. Finally, Nuveen LLC acquired a new position in Thermo Fisher Scientific during the first quarter worth $532,360,000. 89.23% of the stock is owned by hedge funds and other institutional investors.

About Representative Morrison

Kelly Morrison (Democratic Party) is a member of the U.S. House, representing Minnesota's 3rd Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027. Morrison (Democratic Party) is running for re-election to the U.S. House to represent Minnesota's 3rd Congressional District. She declared candidacy for the 2026 election. Kelly Morrison was born in Minneapolis, Minnesota, and lives in Deephaven. Morrison earned a B.A. in history from Yale University and an M.D. from Case Western Reserve University. She completed her residency in obstetrics and gynecology at Northwestern University. Morrison's career experience includes working as a physician.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.